Caflanone - Flavocure Biotech
Alternative Names: FBL-03GLatest Information Update: 28 Apr 2025
At a glance
- Originator Flavocure Biotech
- Class Antineoplastics; Chromones; Phenols; Phenyl ethers; Small molecules
- Mechanism of Action Macrophage colony-stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glioblastoma; Multiple myeloma
- No development reported Pancreatic cancer
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Pancreatic-cancer in USA
- 12 Sep 2022 Preclinical trials in Multiple myeloma in USA (unspecified route) before September 2022 (Flavocure Biotech pipeline, September 2022)
- 25 Mar 2022 Phase-I clinical trials in Pancreatic cancer in USA, (Flavocure Biotech pipeline, March 2022)